Filing Flows › RxSight (RXST) › Q3 2025
RxSight (RXST) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
RxSight (RXST) reported revenue of $30.3M for the third quarter 2025 (Q3 2025), -14% from a year earlier and -10% from the quarter before. Operating margin was -40.1%, net loss $9.8M (32.4% of revenue).
RxSight, Q3 2025: revenue $30.3M (-14% year over year), operating margin -40.1%, net loss $9.8M, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $30.3M | -10% | -14% |
| Operating profit | −$12.2M | — | — |
| Net earnings | −$9.8M | — | — |
| Operating cash flow | −$1.2M | — | — |
What changed
Revenue was $30.3M in Q3 2025, down 14% year over year and down 10% from the previous quarter. Rxlal was the largest line at 85% of revenue. LDD lost $7.0M year over year (down 69%), 140% of the total change.
Gross margin was 79.9%, up 8.4 points from a year earlier. Operating costs exceeded revenue by $12.2M, an operating margin of -40.1%. Operating expenses grew 6% against a revenue fall of 14%. The quarter ended with a net loss of $9.8M, narrower than the previous quarter's $11.8M loss. Non-operating items added $2.4M, -24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.2M. Non-cash charges added back $854K of depreciation and amortization and $8.1M of share-based compensation. Working capital and other items used $333K. Capital expenditures of $581K exceeded it, leaving free cash flow of −$1.8M.
Questions
What was RxSight's revenue in the third quarter 2025?
RxSight (RXST) reported revenue of $30.3M for the third quarter 2025 (Q3 2025), -14% from a year earlier and -10% from the quarter before.
Was RxSight profitable in the third quarter 2025?
Operating loss was $12.2M (-40.1% of revenue) and net loss $9.8M.
Source: RxSight 10-Q on SEC EDGAR.